Table 2.
No. | Compound Name | Substituent (R) | CC50 ± SD a,b | EC50 ± SD a,b | SI с |
---|---|---|---|---|---|
1 |
N6-benzyladenosine (BAPR) |
4.3 ± 1.6 | 0.28 ± 0.05 | 15 | |
2 |
N6-isopenthenyladenosine (iPR) |
6.0 ± 0.6 | 1.0 ± 0.2 | 6.0 | |
3 |
N6-furfuryladenosine (KINR) |
7.8 ± 3.4 | 1.4 ± 0.3 | 5.6 | |
5 | N6-(2-fluorobenzyl) adenosine | 13.3 ± 3.7 | 0.30 ± 0.05 | 44 | |
6 | N6-(3-fluorobenzyl) adenosine | 6.2 ± 1.8 | 0.24 ± 0.09 | 26 | |
7 | N6-(4-fluorobenzyl) adenosine | 2.7 ± 0.9 | 0.14 ± 0.05 | 19 | |
8 | N6-(2,6-difluorobenzyl) adenosine | >254 | 0.21 ± 0.01 | >1210 | |
9 | N6-(2-trifluoromethylbenzyl) adenosine | >235 | 1.0 ± 0.1 | >235 | |
10 | N6-(3-trifluoromethylbenzyl) adenosine | >235 | 0.068 ± 0.001 | >3456 | |
11 | N6-(4-trifluoromethylbenzyl) adenosine | >235 | 1.0 ± 0.1 | >235 |
a All values are in μM and are based on at least three independent dose-response curves; b On rhabdomyosarcoma (RD) cells; c Selectivity Index (SI); SI = CC50/EC50; SD, standard deviation.